The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Employment - Daiichi Sankyo
 
Leadership - Cancer Net Japan; JAMT
Honoraria - Boehringer Ingelheim; Bristol-Myers Squibb; Chugai Foundation for Innovative Drug Discovery Science; Lilly; Merck; MSD; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical; Thermo Fisher Scientific
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Chugai Pharma; Daiichi Sankyo; Guardant Health; Illumina; Lilly; MSD; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical
Research Funding - Abbvie (Inst); Bristol Myers Squibb Foundation (Inst); Daiichi Sankyo (Inst); Kyorin (Inst); Lilly (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Prefered Networ (Inst)
Pooled analysis on characteristics of nausea and vomiting in patients receiving trastuzumab deruxtecan (T-DXd) in clinical studies.
 
Yeon Hee Park
Honoraria - AstraZeneca; Daiichi-Sankyo; Eisai; Lilly; MSD; Novartis; Pfizer; Roche
Consulting or Advisory Role - AstraZeneca; Boryung; Daiichi-Sankyo; Eisai; Gilead Sciences; Lilly; Menarini; MSD; Novartis; Pfizer; Roche
Research Funding - AstraZeneca; Gencurix (Inst); Genome Insight (Inst); NGeneBio (Inst); Pfizer; Roche (Inst)
Travel, Accommodations, Expenses - Gilad
 
Javier Cortés
Stock and Other Ownership Interests - Leuko (I); MAJ3 Capital
Honoraria - AstraZeneca; Celgene; Daiichi Sankyo; Eisai; Gilead Sciences; Lilly; Merck Sharp & Dohme; Novartis; Pfizer; Roche; Samsung; Stemline Therapeutics
Consulting or Advisory Role - Abbvie; AstraZeneca; Athenex; Bioasis; Bioinvent; BioNTech SE; Boehringer Ingelheim; Bridgebio; Celgene; Cellestia Biotech; Clovis Oncology; Daiichi Sankyo; Ellipses Pharma; ERYTECH Pharma; Expres2ion Biotechnologies; GEMoaB; Gilead Sciences; GlaxoSmithKline; HiberCell; Jazz Pharmaceuticals; Leuko; Lilly; Menarini; Merck Sharp & Dohme; Polyphor; Reveal Genomics; Roche; Seagen; SERVIER; Zymeworks
Research Funding - ARIAD (Inst); AstraZeneca (Inst); Baxalta (Inst); Bayer (Inst); Eisai (Inst); Guardant Health (Inst); Merck Sharp & Dohme (Inst); Pfizer (Inst); Piqur (Inst); Puma Biotechnology (Inst); Queen Mary university of London (Inst); Roche (Inst)
Patents, Royalties, Other Intellectual Property - Her2 as a predictor of response to dual HER2 blockade in the absence of cytotoxic therapy.Aleix Prat, Antonio Llombart, Javier Cortés.US 2019/ 0338368 A1; Pharmaceutical Combinations of A Pi3k Inhibitor And A Microtubule Destabilizing Agent. Javier Cortés Castán, Alejandro Piris Giménez, Violeta Serra Elizalde. WO 2014/199294 A.
Travel, Accommodations, Expenses - AstraZeneca; Daiichi Sankyo; Eisai; Gilead Sciences; Merck Sharp&Dhome; Novartis; Pfizer; Roche; Stemline Therapeutics
 
Shanu Modi
Honoraria - AstraZeneca; Daiichi Sankyo/Astra Zeneca; DualityBio; Genentech; Gilead Sciences; Seagen
Consulting or Advisory Role - AstraZeneca; Daiichi Sankyo; DualityBio; Genentech; Gilead Sciences; GlaxoSmithKline; Lilly; Macrogenics; Puma Biotechnology; Seagen; Zymeworks
Research Funding - AstraZeneca (Inst); Daiichi Sankyo (Inst); DualityBio (Inst); Nuvation Bio (Inst); Roche/Genentech (Inst); Seagen (Inst)
 
Sara A. Hurvitz
Stock and Other Ownership Interests - ROM Tech (I)
Research Funding - Ambryx (Inst); Amgen (Inst); Arvinas (Inst); AstraZeneca/Daiichi Sankyo (Inst); Bayer (Inst); Biomarin (Inst); Cascadian Therapeutics (Inst); CytomX Therapeutics (Inst); Daiichi Sankyo (Inst); Dantari (Inst); Dignitana (Inst); G1 Therapeutics (Inst); Genentech/Roche (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Greenwich LifeSciences (Inst); Immunomedics (Inst); Lilly (Inst); Macrogenics (Inst); Merrimack (Inst); Novartis (Inst); OBI Pharma (Inst); Orinove (Inst); Orum (Inst); Pfizer (Inst); Phoenix Molecular Designs (Inst); Pieris Pharmaceuticals (Inst); Puma Biotechnology (Inst); Radius Health (Inst); Samumed (Inst); sanofi (Inst); Seagen (Inst); Zymeworks (Inst)
Travel, Accommodations, Expenses - Lilly
Other Relationship - Pfizer; Roche
 
Giampaolo Bianchini
Honoraria - AstraZeneca/Daiichi Sankyo; Eisai; Exact Sciences; Gilead Sciences; Lilly; Menarini; MSD; Novartis; Pfizer; Roche; Seagen
Consulting or Advisory Role - Agendia; AstraZeneca; AstraZeneca/Daiichi Sankyo; Daiichi Sankyo Europe GmbH; Eisai; Exact Sciences; Gilead Sciences; Lilly; MSD; Novartis; Pfizer; Roche; Seagen
Research Funding - Gilead Sciences (Inst)
Travel, Accommodations, Expenses - AstraZeneca/Daiichi Sankyo; Gilead Sciences; Novartis; Pfizer; Roche
 
Hiroji Iwata
Honoraria - AstraZeneca; Chugai Pharma; Daiichi Sankyo; Eisai; Kyowa Hakko Kirin; Lilly Japan; MSD; Pfizer; Taiho Pharmaceutical
Consulting or Advisory Role - AstraZeneca; Chugai Pharma; Daiichi Sankyo; Kyowa Hakko Kirin; Lilly Japan; MSD; Novartis; Pfizer; Sanofi
Research Funding - Amgen (Inst); AstraZeneca (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Kyowa Hakko Kirin (Inst); Lilly Japan (Inst); MSD (Inst); Nihonkayaku (Inst); Novartis (Inst); Pfizer (Inst); Sanofi (Inst)
 
Kohei Shitara
Honoraria - Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Janssen; Lilly; Ono Pharmaceutical
Consulting or Advisory Role - ALX Oncology; Amgen; Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Daiichi Sankyo; Guardant Health; MSD; Novartis; Ono Pharmaceutical; Takeda; Zymeworks
Research Funding - Amgen (Inst); Astellas Pharma (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Eisai (Inst); MSD (Inst); Ono Pharmaceutical (Inst); PRA Health Sciences (Inst); Taiho Pharmaceutical (Inst)
 
Salvatore Siena
Stock and Other Ownership Interests - Guardant Health; Myriad Genetics
Consulting or Advisory Role - Agenus; AstraZeneca; Bayer; Bristol-Myers Squibb; CheckmAb; Daiichi Sankyo; GlaxoSmithKline; Merck; MSD Oncology; Novartis; Pierre Fabre; Pierre Fabre; Seagen; T-One Therapeutics
Research Funding - MSD Oncology (Inst)
Patents, Royalties, Other Intellectual Property - Amgen
Travel, Accommodations, Expenses - Amgen; Bayer; Roche
 
Yasushi Goto
No Relationships to Disclose
 
Geoffrey Yuyat Ku
Consulting or Advisory Role - Apexigen; AstraZeneca/Daiichi Sankyo; Bristol-Myers Squibb; I-Mab; Jazz Pharmaceuticals; Merck Sharp & Dohme; Pieris Pharmaceuticals
Research Funding - Adaptimmune (Inst); Arog (Inst); AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); CARsgen Therapeutics (Inst); Daiichi Sankyo (Inst); Jazz Pharmaceuticals (Inst); Merck (Inst); Oncolys BioPharma (Inst); Pieris Pharmaceuticals (Inst); Triumvira Immunologics, Inc (Inst); Zymeworks (Inst)
Travel, Accommodations, Expenses - Aduro Biotech; AstraZeneca/MedImmune; Bristol-Myers Squibb; ImaBiotech; Merck Sharp & Dohme; Pieris Pharmaceuticals
 
Powell Andrew Charles
Honoraria - AstraZeneca
Consulting or Advisory Role - Aptar Digital Health; BioNTech SE; Bristol-Myers Squibb/Roche; Daiichi Sankyo/Astra Zeneca; Duality Biologics; Eisai; Merus NV; Pfizer; Seagen; Silverback Therapeutics
Patents, Royalties, Other Intellectual Property - US11004196B2 Advanced computer-aided diagnosis of lung nodules. (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Duality Biologics
 
Sandra M. Swain
Leadership - Seagen; Seagen
Stock and Other Ownership Interests - SEAGEN
Honoraria - Chugai/Roche
Consulting or Advisory Role - AstraZeneca; Aventis Pharma; Daiichi Sankyo; Genentech/Roche; Jaguar Health; Molecular Templates
Travel, Accommodations, Expenses - Aventis Pharma; Chugai/Roche; Daichi Sankyo; Genentech/Roche
Other Relationship - AstraZeneca; Roche
(OPTIONAL) Uncompensated Relationships - Genentech/Roche
 
Meena Arunachalam
Employment - Daiichi Sankyo Inc
Stock and Other Ownership Interests - Daiichi Sankyo Inc
 
Martin Janek
Employment - Daiichi Sankyo
Stock and Other Ownership Interests - Merck - MRK
 
Yingkai Cheng
Employment - Daiichi Sankyo
Stock and Other Ownership Interests - Daiichi Sankyo
Travel, Accommodations, Expenses - Daiichi Sankyo
 
Changan Chu
No Relationships to Disclose
 
Purnima Verma
Employment - Daiichi Sankyo
 
Elton Mathias
Employment - Daiichi Sankyo
 
Maha Karnoub
Employment - Daiichi Sankyo
Stock and Other Ownership Interests - Daiichi Sankyo
 
Hope S. Rugo
Consulting or Advisory Role - Daiichi Sankyo; Eisai; Mylan; Napo Pharmaceuticals; Puma Biotechnology
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Daiichi Sankyo (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Hoffmann-La Roche AG/Genentech, Inc (Inst); Lilly (Inst); Merck (Inst); Novartis (Inst); OBI Pharma (Inst); Pfizer (Inst); Stemline Therapeutics (Inst); Taiho Oncology (Inst); Veru (Inst)